In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, with a price target of $89.00. The company’s shares closed yesterday at $39.61.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Travere Therapeutics, and Madrigal Pharmaceuticals. According to TipRanks, Nash has an average return of 17.0% and a 47.38% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Apogee Therapeutics with a $90.88 average price target, which is a 129.44% upside from current levels. In a report released on September 25, RBC Capital also initiated coverage with a Buy rating on the stock with a $60.00 price target.
The company has a one-year high of $63.50 and a one-year low of $26.20. Currently, Apogee Therapeutics has an average volume of 733.7K.
Read More on APGE:
Disclaimer & DisclosureReport an Issue
- Apogee Therapeutics initiated with an Outperform at RBC Capital
- Wall Street Sees Massive Growth Potential in These 3 Russell 2000 Stocks
- 3 Best Stocks to Buy Now, 8/28/2025, According to Top Analysts
- Apogee Therapeutics price target raised to $87 from $78 at BofA
- Promising Prospects for Apogee Therapeutics: Buy Rating Backed by Strong Trial Results and Financial Health
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)